Enrichment of CD103+ CD4+ T cells in bone metastases compared to non-malignant controls
In conclusion, BoM exhibit a distinct T-cell composition, highlighted by an increase in CD103⁺CD4⁺ cells displaying an increased CM phenotype. In BoM, cregulatory receptor expression is increased on CD103⁺ T cells, with distinct coexpression signatures in both CD4⁺ and CD8⁺ cells. Functional studies will determine whether targeting these checkpoint pathways can improve immunotherapy for metastatic bone disease.
Authors
- Julian Kylies
- Leon-Gordian Leonhardt
- Jasmin Wellbrock (ORCID: https://orcid.org/0000-0001-8067-2314)
- Lennart Viezens (ORCID: https://orcid.org/0000-0001-9353-667X)
- Franziska Brauneck (ORCID: https://orcid.org/0000-0002-0026-3658)
- Walter Fiedler (ORCID: https://orcid.org/0000-0003-0275-8803)
- Niklas Kruppa
- Elias Brauneck
- Y. Wahid
- Anne Marie Assemissen
- Moritz Kruppa
Institutions
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- University Cancer Center Hamburg (DE)
Publication Details
- Journal
- Immunology Letters
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1016/j.imlet.2026.107135
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00